LinqMed and PeptiDream Announce Strategic Partnership for the Development and Commercialization of 64Cu-ATSM
Sun Gwan Hwang
SK Biopharmaceuticals Vice President, R&D Innovation; Where Digital Meets Humanity. - ???? ???.
hypoxia-targeted(Hif-1a) internal radiotherapy agent, 64Cu-diacetyl-bis (N4-methylthiosemicarbazone) (64Cu-ATSM)
ref:
PC data: Multiple Administrations of 64Cu-ATSM as a Novel Therapeutic Option for Glioblastoma: a Translational Study Using Mice with Xenografts - PubMed (nih.gov)
P1: Phase I clinical trial of 64Cu-ATSM for malignant brain tumors. | Journal of Clinical Oncology (ascopubs.org)